Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
暂无分享,去创建一个
A. Ganser | G. Mufti | B. Quesnel | L. Nilsson | M. Lübbert | P. Fenaux | E. Hellström-Lindberg | A. Giagounidis | D. Bowen | U. Platzbecker | M. Mittelman | B. Schlegelberger | G. Göhring | G. Sanz | O. Beyne-Rauzy | P. Muus | D. Selleslag | C. del Cañizo | A. Guerci-Bresler | P. T. te Boekhorst | T. Fu | B. Benettaib
[1] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[2] R. Schlenk,et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.
[3] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Fenaux,et al. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. , 2011, Leukemia research.
[5] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[6] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[7] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[8] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Catherine Klersy,et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes , 2007, British journal of haematology.
[10] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[11] U. Germing,et al. Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies , 2006, Clinical Cancer Research.
[12] J. Cigudosa,et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. , 2005, Haematologica.
[13] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[14] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[15] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.